STAAR Surgical (NASDAQ:STAA) Major Shareholder Buys $2,155,022.94 in Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 138,054 shares of the company’s stock in a transaction on Monday, April 7th. The shares were purchased at an average cost of $15.61 per share, with a total value of $2,155,022.94. Following the transaction, the insider now directly owns 13,332,264 shares in the company, valued at $208,116,641.04. This trade represents a 1.05 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Friday, April 4th, Broadwood Partners, L.P. purchased 497,631 shares of STAAR Surgical stock. The shares were acquired at an average price of $15.91 per share, for a total transaction of $7,917,309.21.
• On Wednesday, April 2nd, Broadwood Partners, L.P. acquired 31,780 shares of STAAR Surgical stock. The stock was acquired at an average price of $17.43 per share, for a total transaction of $553,925.40.
• On Monday, March 31st, Broadwood Partners, L.P. bought 22,189 shares of STAAR Surgical stock. The shares were acquired at an average price of $17.46 per share, with a total value of $387,419.94.
• On Thursday, March 27th, Broadwood Partners, L.P. acquired 3,620 shares of STAAR Surgical stock. The shares were bought at an average cost of $17.48 per share, for a total transaction of $63,277.60.
• On Tuesday, March 25th, Broadwood Partners, L.P. bought 34,296 shares of STAAR Surgical stock. The stock was bought at an average cost of $17.44 per share, with a total value of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. purchased 108,720 shares of STAAR Surgical stock. The shares were bought at an average price of $17.96 per share, for a total transaction of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. bought 93,124 shares of STAAR Surgical stock. The shares were purchased at an average price of $17.54 per share, for a total transaction of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. bought 249,503 shares of STAAR Surgical stock. The stock was purchased at an average price of $16.64 per share, with a total value of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. purchased 259,316 shares of STAAR Surgical stock. The stock was purchased at an average cost of $17.05 per share, for a total transaction of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock. The shares were purchased at an average cost of $15.49 per share, with a total value of $565,880.68.

STAAR Surgical Trading Up 1.4 %

STAA stock traded up $0.22 during midday trading on Monday, hitting $16.14. The company’s stock had a trading volume of 1,526,031 shares, compared to its average volume of 784,406. The firm’s 50-day moving average is $18.65 and its 200-day moving average is $24.55. STAAR Surgical has a 12 month low of $13.50 and a 12 month high of $52.68. The company has a market cap of $796.11 million, a PE ratio of -39.37 and a beta of 0.75.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on STAA shares. Piper Sandler decreased their price target on shares of STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating for the company in a research note on Wednesday, February 12th. William Blair downgraded shares of STAAR Surgical from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 12th. Canaccord Genuity Group lowered their target price on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating for the company in a report on Thursday, February 13th. BTIG Research downgraded STAAR Surgical from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research report on Thursday, February 27th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, STAAR Surgical has an average rating of “Hold” and a consensus target price of $25.29.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Quarry LP bought a new stake in STAAR Surgical in the 3rd quarter worth about $50,000. KLP Kapitalforvaltning AS bought a new position in STAAR Surgical during the 4th quarter valued at about $180,000. GAMMA Investing LLC boosted its holdings in shares of STAAR Surgical by 4,086.0% during the 1st quarter. GAMMA Investing LLC now owns 14,651 shares of the medical instruments supplier’s stock valued at $258,000 after acquiring an additional 14,301 shares during the last quarter. Bridgefront Capital LLC grew its stake in shares of STAAR Surgical by 27.2% in the fourth quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier’s stock worth $262,000 after acquiring an additional 2,306 shares during the period. Finally, FMR LLC raised its holdings in shares of STAAR Surgical by 79.3% during the third quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier’s stock valued at $263,000 after purchasing an additional 3,136 shares during the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.